Study of HB0025 plus chemo vs. standard chemo for first-line advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called HB0025 combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before. It compares this combination to the current standard treatment (tislelizumab plus chemo) to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced (stage IIIB/IIIC or IV) non-squamous non-small cell lung cancer that cannot be removed by surgery or treated with chemoradiation.
- You cannot have had any prior systemic treatment for your lung cancer.
- Your cancer must not have certain genetic changes (like EGFR or ALK) that have approved targeted treatments.
- You need to have at least one tumor that can be measured on scans (not in the brain) and provide a tumor tissue sample for testing.
- You must be generally healthy enough for treatment, with good organ function and a performance status of 0 or 1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with a type of lung cancer that has spread or cannot be removed by surgery. It compares the new combination to the current standard treatment to see which works better.
This trial compares a new drug, HB0025, combined with chemotherapy against the standard treatment (pembrolizumab plus chemotherapy) as a first treatment for advanced squamous non-small cell lung cancer that cannot be removed by surgery or has spread. It aims to see if HB0025 is more effective and safe.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug called HB0025 for people with advanced non-small cell lung cancer or endometrial cancer that cannot be removed by surgery. The study aims to see if the drug is safe and effective.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a new drug combined with chemotherapy compared to a standard immunotherapy combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the new combination is more effective and may offer a new first-line treatment option.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.